Should I buy Lilly (Eli) (LLY) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $1,430 (+23 %), call made on October 8, 2026, maturing on October 8, 2027 (6 d ago).
Firm-by-firm track record on Lilly (Eli)
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 100 % | +50.2 % | 6 | $1,425 +22% |
| Morgan Stanley | 90 % | +49.8 % | 42 | $1,430 +23% |
| Wells Fargo | 91 % | +45.5 % | 11 | $1,330 +14% |
| Guggenheim | 80 % | +40.2 % | 10 | $1,284 +10% |
| JP Morgan | 89 % | +38.9 % | 18 | $1,500 +29% |
| Truist Securities | 86 % | +37.0 % | 14 | $1,376 +18% |
| Citigroup | 91 % | +32.2 % | 11 | $1,600 +37% |
| Cantor Fitzgerald | 66 % | +27.0 % | 47 | $1,440 +23% |
✅ Reasons to believe
- 94% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
- Median price target $1,376, i.e. +18% from the current price ($1,167).
- 6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- Even the most reliable firm on LLY, HSBC (100% hit rate, 2 scored calls), only targets $940 (call made on September 10, 2026, maturing on September 10, 2027) (-19%) in its most recent call, and $850 (call made on March 17, 2026, maturing on March 17, 2027) (-27%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 17 ratings, 1 is a sell.
- High valuation (P/E ~39): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on LLY
Median target $1,376 (+18%) · 17 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Lilly (Eli) now?
We won't decide for you. The facts: 94% of analysts rate it a buy, median target $1,376 (+18%), and HSBC (most reliable on LLY, 100%) targets $940. Weigh that against valuation (P/E ~39). This is not personalized advice.
Is it too late to invest in Lilly (Eli)?
Not according to analysts: the median target ($1,376) is still +18% above the current price ($1,167) (most reliable on LLY: HSBC, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Lilly (Eli) still worth investing in?
It depends on the gap between the price ($1,167) and its estimated value: analysts target $1,376 on median (+18%), with 94% buys (most reliable on LLY: HSBC, 100%). Cross-check with their real reliability on LLY and the cautions above. Information, not advice.
What's the main risk in buying LLY?
Even the most reliable firm on LLY, HSBC (100% hit rate, 2 scored calls), only targets $940 (call made on September 10, 2026, maturing on September 10, 2027) (-19%) in its most recent call, and $850 (call made on March 17, 2026, maturing on March 17, 2027) (-27%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Lilly (Eli) profile (consensus, analyst reliability, price target, performance).